Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: etrolizumab, firategrast, natalizumab +2 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | PubMed did not answer (PubMed: HTTP 500) | 0.00 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 17057
Sealed predictions
- ITGB7 in dopamine neurons, braak-0.35 (p 0.349) → +0.17 (p 0.663)receipt 17064
Swarm cases
receipt 17064: ITGB7 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.221, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.019, n 18). not the mix.
- skeptic
- leave-one-out range -0.38 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGB7 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts